Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Operating Expenses (2016 - 2025)

Historic Operating Expenses for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to $51.6 million.

  • UroGen Pharma's Operating Expenses rose 2802.76% to $51.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $218.3 million, marking a year-over-year increase of 3278.16%. This contributed to the annual value of $178.3 million for FY2024, which is 2837.61% up from last year.
  • Per UroGen Pharma's latest filing, its Operating Expenses stood at $51.6 million for Q3 2025, which was up 2802.76% from $62.1 million recorded in Q2 2025.
  • UroGen Pharma's Operating Expenses' 5-year high stood at $62.1 million during Q2 2025, with a 5-year trough of $32.0 million in Q3 2023.
  • For the 5-year period, UroGen Pharma's Operating Expenses averaged around $39.8 million, with its median value being $35.9 million (2023).
  • As far as peak fluctuations go, UroGen Pharma's Operating Expenses plummeted by 412.26% in 2022, and later soared by 3876.66% in 2024.
  • Quarter analysis of 5 years shows UroGen Pharma's Operating Expenses stood at $34.5 million in 2021, then rose by 4.67% to $36.1 million in 2022, then dropped by 0.71% to $35.9 million in 2023, then surged by 38.77% to $49.8 million in 2024, then rose by 3.69% to $51.6 million in 2025.
  • Its last three reported values are $51.6 million in Q3 2025, $62.1 million for Q2 2025, and $54.8 million during Q1 2025.